See more : Beroni Group Limited (BNIGF) Income Statement Analysis – Financial Results
Complete financial analysis of Talphera, Inc. (TLPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Talphera, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Altimeter Growth Corp. (AGC) Income Statement Analysis – Financial Results
- Quinsam Capital Corporation (QCA.CN) Income Statement Analysis – Financial Results
- Bausen Inc. (2948.TWO) Income Statement Analysis – Financial Results
- Kaken Pharmaceutical Co., Ltd. (KKPCF) Income Statement Analysis – Financial Results
- Akikawa Foods & Farms Co., Ltd. (1380.T) Income Statement Analysis – Financial Results
Talphera, Inc. (TLPH)
About Talphera, Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 651.00K | 1.77M | 2.82M | 5.42M | 2.29M | 2.15M | 8.00M | 17.36M | 19.26M | 5.22M | 29.50M | 2.39M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.55M | 2.59M | 3.75M | 6.03M | 6.81M | 3.98M | 10.66M | 12.32M | 24.26M | 24.52M | 26.29M | 605.00K | 0.00 | 479.00K | 481.00K | 383.00K | 216.00K |
| Gross Profit | -4.90M | -820.00K | -935.00K | -616.00K | -4.52M | -1.83M | -2.66M | 5.04M | -5.00M | -19.30M | 3.21M | 1.79M | 1.07M | -479.00K | -481.00K | -383.00K | -216.00K |
| Gross Profit Ratio | -751.92% | -46.30% | -33.18% | -11.37% | -197.34% | -84.84% | -33.32% | 29.05% | -25.93% | -370.00% | 10.88% | 74.73% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.55M | 3.34M | 4.10M | 4.02M | 4.66M | 13.14M | 19.41M | 21.40M | 22.49M | 24.52M | 26.29M | 24.91M | 13.62M | 8.19M | 15.50M | 18.33M | 8.21M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 43.93M | 20.27M | 0.00 | 15.60M | 14.20M | 18.35M | 9.88M | 7.20M | 6.80M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 1.10M | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.99M | 17.01M | 30.94M | 36.33M | 45.03M | 20.77M | 16.61M | 15.60M | 14.20M | 18.35M | 9.88M | 7.20M | 6.80M | 3.51M | 3.05M | 1.98M | 1.87M |
| Other Expenses | 0.00 | 84.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.54M | 20.35M | 35.03M | 40.35M | 49.69M | 33.90M | 36.02M | 37.00M | 13.32M | 11.41M | 25.15M | 32.11M | 20.42M | 11.71M | 18.55M | 20.31M | 10.08M |
| Cost & Expenses | 17.54M | 20.35M | 38.78M | 46.38M | 56.49M | 37.88M | 46.68M | 49.31M | 37.58M | 35.93M | 51.44M | 32.11M | 20.42M | 12.19M | 19.03M | 20.69M | 10.29M |
| Interest Income | 6.74M | 1.50M | 3.16M | 3.89M | 1.28M | 11.42M | 13.83M | 12.00M | 5.32M | 2.64M | 1.49M | 0.00 | 1.56M | 4.00K | 33.00K | 484.00K | 687.00K |
| Interest Expense | 134.00K | 1.12M | 2.29M | 3.31M | 2.54M | 12.56M | 14.04M | 12.15M | 5.41M | 2.64M | 16.76M | 3.65M | 2.31M | 1.40M | 1.24M | 404.00K | 25.00K |
| Depreciation & Amortization | 311.00K | 1.65M | 1.97M | 1.85M | 1.67M | 575.00K | 1.74M | 2.05M | 1.98M | 866.00K | 593.00K | 605.00K | 513.00K | 479.00K | 481.00K | 383.00K | 216.00K |
| EBITDA | -9.84M | -17.20M | -30.83M | -35.22M | -49.03M | -34.01M | -36.43M | -28.99M | -16.25M | -29.85M | -6.07M | -29.11M | -17.28M | -12.47M | -18.40M | -19.88M | -9.39M |
| EBITDA Ratio | -1,511.83% | -971.37% | -1,094.04% | -650.24% | -2,295.19% | -1,634.22% | -462.01% | -172.29% | -89.36% | -705.06% | -20.59% | -1,215.87% | -1,611.85% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -16.89M | -25.30M | -35.97M | -40.96M | -54.21M | -35.73M | -38.68M | -31.96M | -19.20M | -37.65M | -6.67M | -29.71M | -19.35M | -12.19M | -19.03M | -20.69M | -10.29M |
| Operating Income Ratio | -2,594.32% | -1,428.57% | -1,276.26% | -756.33% | -2,368.06% | -1,660.95% | -483.83% | -184.12% | -99.66% | -721.66% | -22.60% | -1,241.14% | -1,805.22% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.60M | 84.44M | 871.00K | 588.00K | 968.00K | -11.42M | -13.53M | -11.23M | -4.44M | 4.30M | -16.76M | -3.65M | -749.00K | -2.16M | -1.09M | 28.00K | 661.00K |
| Income Before Tax | -10.29M | 59.14M | -35.09M | -40.38M | -53.24M | -47.15M | -52.21M | -43.19M | -23.64M | -33.35M | -23.43M | -33.36M | -20.10M | -14.34M | -20.12M | -20.66M | -9.63M |
| Income Before Tax Ratio | -1,580.18% | 3,339.24% | -1,245.35% | -745.48% | -2,325.78% | -2,191.86% | -653.02% | -248.84% | -122.72% | -639.31% | -79.40% | -1,393.61% | -1,875.09% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 13.00K | 5.00K | 4.00K | 3.00K | 2.00K | -701.00K | -34.00K | 760.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -18.40M | 47.76M | -35.10M | -40.38M | -53.24M | -47.15M | -51.51M | -43.16M | -24.40M | -33.35M | -23.43M | -33.36M | -20.10M | -14.34M | -20.12M | -20.66M | -9.63M |
| Net Income Ratio | -2,825.96% | 2,696.50% | -1,245.53% | -745.55% | -2,325.91% | -2,191.96% | -644.25% | -248.64% | -126.66% | -639.31% | -79.40% | -1,393.61% | -1,875.09% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.29 | 5.73 | -5.86 | -9.47 | -13.45 | -16.14 | -21.97 | -19.05 | -11.93 | -18.20 | -11.80 | -30.16 | -23.18 | -13.95 | -19.56 | -20.09 | -9.36 |
| EPS Diluted | -1.29 | 5.72 | -5.86 | -9.47 | -13.45 | -16.14 | -21.97 | -19.05 | -10.97 | -15.05 | -11.79 | -30.16 | -23.18 | -13.95 | -19.56 | -20.09 | -9.36 |
| Weighted Avg Shares Out | 14.26M | 7.41M | 5.99M | 4.26M | 3.96M | 2.92M | 2.34M | 2.27M | 2.05M | 1.83M | 1.99M | 1.11M | 867.24K | 1.03M | 1.03M | 1.03M | 1.03M |
| Weighted Avg Shares Out (Dil) | 14.26M | 7.41M | 5.99M | 4.26M | 3.96M | 2.92M | 2.34M | 2.27M | 2.22M | 2.22M | 1.99M | 1.11M | 867.24K | 1.03M | 1.03M | 1.03M | 1.03M |
Talphera to Participate at A.G.P. Virtual Healthcare Conference
SAN MATEO, Calif. , May 16, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a...
Talphera, Inc. (TLPH) Q1 2024 Earnings Call Transcript
Talphera, Inc. (NASDAQ:TLPH ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vince Angotti - Chief Executive Officer Pam Palmer - Founder and Chief Medical Officer Conference Call Participants...
Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update
First patients at multiple sites are expected to be enrolled in the NEPHRO CRRT registrational study in Q2 2024 Dr. Shakil Aslam, an expert in renal diseases, including acute kidney injury, joins Talphera as Chief Development Officer Cash and investments...
Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024
SAN MATEO, Calif., May 2, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2024...
Talphera, Inc. (TLPH) Q4 2023 Earnings Call Transcript
Talphera, Inc. (NASDAQ:TLPH ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Pamela Palmer - Chief Medical Officer and Co-Founder Conference Call Participants...
Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
Company rebranding and corporate transformation to Talphera completed in Q1 2024 First patient enrollment in the NEPHRO CRRT registrational study expected in Q1 2024 with a projected PMA submission by the end of 2024 Cash and investments at December 31,...
Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
SAN MATEO, Calif. , March 1, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced as part of its commitment to...
Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024
SAN MATEO, Calif. , Feb. 26, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release fourth...
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
The total committed funding is expected to provide sufficient capital to fund Talphera through a potential FDA approval of Niyad™, targeted for the first half of 2025 $16 million of total equity committed with $6 million upfront and $10 million...
Source: https://incomestatements.info
Category: Stock Reports